NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route (Ascending) | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
47781-0610-23 | 47781-0610 | Cisplatin | Cisplatin | 100.0 mg/100mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 25, 2017 | March 1, 2020 | No Longer Used |
50742-0405-10 | 50742-0405 | Oxaliplatin | Oxaliplatin | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct. 29, 2018 | In Use | |
50742-0406-20 | 50742-0406 | Oxaliplatin | Oxaliplatin | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct. 29, 2018 | In Use | |
51808-0128-01 | 51808-0128 | P32 Sodium Phosphate | P32 Sodium Phosphate | 10.0 mCi/4mL | Chemotherapy | Radiopharmaceutical | Phosphorus 32 | Intravenous | June 19, 2012 | In Use | |
51991-0218-98 | 51991-0218 | Oxaliplatin | Oxaliplatin | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 1, 2017 | Oct. 31, 2020 | No Longer Used |
51991-0922-98 | 51991-0922 | Oxaliplatin | Oxaliplatin | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 22, 2017 | March 31, 2019 | No Longer Used |
51991-0923-98 | 51991-0923 | Oxaliplatin | Oxaliplatin | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 22, 2017 | May 31, 2019 | No Longer Used |
51991-0937-98 | 51991-0937 | Paclitaxel | Paclitaxel | 100.0 mg/16.7mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 22, 2017 | March 31, 2019 | No Longer Used |
51991-0938-98 | 51991-0938 | Paclitaxel | Paclitaxel | 300.0 mg/50mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | May 22, 2017 | May 31, 2019 | No Longer Used |
53150-0314-01 | 53150-0314 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 20.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 30, 2013 | Dec. 31, 2017 | No Longer Used |
53150-0314-10 | 53150-0314 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 20.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 30, 2013 | Dec. 31, 2017 | No Longer Used |
53150-0315-01 | 53150-0315 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 50.0 mg/25mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 30, 2013 | Dec. 31, 2017 | No Longer Used |
53150-0317-01 | 53150-0317 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 200.0 mg/100mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 30, 2013 | Dec. 31, 2017 | No Longer Used |
53150-0320-01 | 53150-0320 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 10.0 mg/5mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 30, 2013 | Dec. 31, 2017 | No Longer Used |
53150-0320-10 | 53150-0320 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 10.0 mg/5mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 30, 2013 | Dec. 31, 2017 | No Longer Used |
44087-3535-01 | 44087-3535 | Avelumab | Bavencio | 20.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | March 23, 2017 | In Use | |
50742-0404-01 | 50742-0404 | Topotecan | Topotecan | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 7, 2016 | In Use | |
50742-0423-10 | 50742-0423 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 21, 2019 | In Use | |
50742-0428-02 | 50742-0428 | Docetaxel Anhydrous | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sept. 7, 2017 | April 30, 2021 | In Use |
50742-0420-01 | 50742-0420 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Aug. 8, 2019 | In Use | |
50742-0427-05 | 50742-0427 | Vinorelbine | Vinorelbine | 50.0 mg/5mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Aug. 8, 2019 | In Use | |
50742-0445-05 | 50742-0445 | Carboplatin | Carboplatin | 50.0 mg/5mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 6, 2017 | Feb. 12, 2018 | In Use |
50742-0446-15 | 50742-0446 | Carboplatin | Carboplatin | 150.0 mg/15mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 6, 2017 | Feb. 12, 2018 | In Use |
50742-0481-20 | 50742-0481 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 21, 2019 | In Use | |
50742-0482-50 | 50742-0482 | fluorouracil | FLUOROURACIL | 2.5 g/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 21, 2019 | In Use | |
50742-0483-99 | 50742-0483 | fluorouracil | FLUOROURACIL | 5.0 g/100mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 21, 2019 | In Use | |
50742-0512-20 | 50742-0512 | Clofarabine | Clofarabine | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Sept. 27, 2018 | In Use | |
50742-0525-07 | 50742-0525 | arsenic trioxide | ARSENIC TRIOXIDE | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Jan. 27, 2021 | In Use | |
72187-0401-01 | 72187-0401 | Tagraxofusp | Elzonris | 1000.0 ug/mL | Immunotherapy | Fusion Protein | IL3/ CD123 | Intravenous | Jan. 18, 2019 | In Use | |
73380-4700-01 | 73380-4700 | MOXETUMOMAB PASUDOTOX | LUMOXITI | 1.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | CD22 | Intravenous | May 15, 2020 | In Use | |
51144-0003-01 | 51144-0003 | Tisotumab vedotin | TIVDAK | 40.0 mg/4mL | Immunotherapy | Drug Antibody Conjugate | Tissue factor | Intravenous | Sept. 20, 2021 | In Use | |
57277-0107-45 | 57277-0107 | carboplatin Injection | Carboplatin | 450.0 mg/5mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 29, 2016 | In Use | |
57884-3021-00 | 57884-3021 | Docetaxel | Docetaxel | 40.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 15, 2017 | Oct. 29, 2021 | In Use |
59148-0047-91 | 59148-0047 | Busulfan | Busulfex | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Feb. 13, 2015 | Jan. 31, 2021 | No Longer Used |
59148-0070-91 | 59148-0070 | Busulfan | Busulfex | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Feb. 4, 1999 | In Use | |
59676-0960-01 | 59676-0960 | Doxorubicin Hydrochloride | Doxil | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Nov. 17, 1995 | Sept. 30, 2020 | No Longer Used |
59676-0960-02 | 59676-0960 | Doxorubicin Hydrochloride | Doxil | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Nov. 17, 1995 | June 30, 2020 | No Longer Used |
59676-0966-01 | 59676-0966 | doxorubicin hydrochloride | Doxorubicin Hydrochloride liposome | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | June 26, 2017 | Sept. 30, 2020 | No Longer Used |
59676-0966-02 | 59676-0966 | doxorubicin hydrochloride | Doxorubicin Hydrochloride liposome | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | June 26, 2017 | Oct. 31, 2020 | No Longer Used |
60505-6113-06 | 60505-6113 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 20, 2018 | Jan. 31, 2021 | No Longer Used |
60505-6114-00 | 60505-6114 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 20, 2018 | Jan. 31, 2021 | No Longer Used |
60505-6115-02 | 60505-6115 | GEMCITABINE HYDROCHLORIDE | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 20, 2018 | Jan. 31, 2021 | No Longer Used |
61126-0003-10 | 61126-0003 | Cisplatin | Platinol | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 13, 2012 | Jan. 13, 2012 | In Use |
61126-0004-01 | 61126-0004 | Cisplatin | Platinol-AQ | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 13, 2012 | In Use | |
61126-0004-02 | 61126-0004 | Cisplatin | Platinol-AQ | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 13, 2012 | Jan. 13, 2012 | In Use |
61703-0303-46 | 61703-0303 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug. 31, 1990 | In Use | |
61703-0341-06 | 61703-0341 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | April 9, 2007 | Oct. 31, 2017 | No Longer Used |
61703-0341-09 | 61703-0341 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | April 2, 2007 | May 31, 2019 | No Longer Used |
61703-0344-18 | 61703-0344 | Fludarabine Phosphate | Fludarabine Phosphate | 50.0 mg/2mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Sept. 25, 2008 | Sept. 30, 2021 | No Longer Used |
62756-0826-40 | 62756-0826 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb. 20, 2012 | In Use | |
62756-0827-40 | 62756-0827 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Feb. 20, 2012 | In Use | |
62856-0600-01 | 62856-0600 | Decitabine | Dacogen | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 3, 1996 | Dec. 31, 2018 | No Longer Used |
63323-0637-10 | 63323-0637 | Arsenic Trioxide | Arsenic Trioxide | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Aug. 31, 2018 | In Use | |
63459-0600-10 | 63459-0600 | Arsenic Trioxide | Trisenox | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Oct. 15, 2000 | Aug. 15, 2021 | No Longer Used |
63739-0932-11 | 63739-0932 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 1, 2015 | March 31, 2017 | In Use |
63739-0971-17 | 63739-0971 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 1, 2015 | March 31, 2017 | In Use |
63759-0003-01 | 63759-0003 | azacitidine for | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Dec. 5, 2016 | In Use | |
64370-0532-01 | 64370-0532 | Vinorelbine tartrate | Navelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Nov. 15, 2005 | Oct. 31, 2021 | No Longer Used |
64370-0532-02 | 64370-0532 | Vinorelbine tartrate | Navelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Nov. 15, 2005 | Oct. 31, 2021 | No Longer Used |
66435-0410-01 | 66435-0410 | Topotecan Hydrochloride | Topotecan Hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 2, 2010 | Oct. 31, 2014 | No Longer Used |
66435-0410-05 | 66435-0410 | Topotecan Hydrochloride | Topotecan Hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 2, 2010 | Oct. 31, 2014 | No Longer Used |
66758-0042-01 | 66758-0042 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec. 22, 2009 | May 31, 2014 | In Use |
66758-0042-02 | 66758-0042 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec. 22, 2009 | May 31, 2014 | In Use |
66758-0043-01 | 66758-0043 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 2, 2008 | Feb. 7, 2016 | In Use |
66758-0043-02 | 66758-0043 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 2, 2008 | Feb. 7, 2016 | In Use |
66758-0043-03 | 66758-0043 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jan. 2, 2008 | Feb. 7, 2016 | In Use |
66758-0044-01 | 66758-0044 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Sept. 10, 2008 | Oct. 7, 2014 | In Use |
66758-0044-03 | 66758-0044 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Sept. 10, 2008 | Oct. 7, 2014 | In Use |
66758-0047-01 | 66758-0047 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 31, 2010 | March 15, 2015 | In Use |
66758-0047-02 | 66758-0047 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 31, 2010 | July 15, 2015 | In Use |
66758-0047-03 | 66758-0047 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 31, 2010 | July 19, 2015 | In Use |
66758-0047-04 | 66758-0047 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 31, 2010 | May 2, 2015 | In Use |
66758-0048-01 | 66758-0048 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov. 30, 2009 | May 27, 2018 | In Use |
66758-0048-02 | 66758-0048 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov. 30, 2009 | May 27, 2018 | In Use |
66758-0051-01 | 66758-0051 | Topotecan | Topotecan | 1.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 25, 2011 | In Use | |
66758-0051-03 | 66758-0051 | Topotecan | Topotecan | 1.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 25, 2011 | In Use | |
66758-0051-05 | 66758-0051 | Topotecan | Topotecan | 1.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 25, 2011 | In Use | |
66758-0054-01 | 66758-0054 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 2, 2011 | May 2, 2011 | In Use |
66758-0054-02 | 66758-0054 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 2, 2011 | May 2, 2011 | In Use |
66758-0055-01 | 66758-0055 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | March 29, 2011 | March 29, 2011 | In Use |
66758-0055-03 | 66758-0055 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | March 29, 2011 | March 29, 2011 | In Use |
66758-0055-05 | 66758-0055 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | March 29, 2011 | March 29, 2011 | In Use |
67457-0434-51 | 67457-0434 | Paclitaxel | Paclitaxel | 300.0 mg/50mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 7, 2014 | March 31, 2021 | No Longer Used |
67457-0449-17 | 67457-0449 | Paclitaxel | Paclitaxel | 100.0 mg/16.7mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 7, 2014 | Oct. 31, 2020 | No Longer Used |
67457-0454-50 | 67457-0454 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Dec. 14, 2011 | Dec. 31, 2021 | No Longer Used |
67457-0462-01 | 67457-0462 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 1.0 g/25mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Sept. 22, 2014 | April 30, 2021 | No Longer Used |
67457-0463-02 | 67457-0463 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 2.0 g/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 24, 2014 | June 30, 2021 | No Longer Used |
67457-0464-20 | 67457-0464 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 24, 2014 | June 30, 2021 | No Longer Used |
67457-0468-50 | 67457-0468 | Oxaliplatin | Oxaliplatin | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug. 9, 2012 | Dec. 31, 2017 | No Longer Used |
67457-0471-52 | 67457-0471 | Paclitaxel | Paclitaxel | 30.0 mg/5mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 7, 2014 | Feb. 28, 2021 | No Longer Used |
67457-0474-04 | 67457-0474 | Topotecan Hydrochloride | Topotecan Hydrochloride | 4.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug. 29, 2012 | Dec. 31, 2017 | No Longer Used |
67457-0476-10 | 67457-0476 | Oxaliplatin | Oxaliplatin | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug. 9, 2012 | Dec. 31, 2017 | No Longer Used |
68001-0282-22 | 68001-0282 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 25, 2011 | Aug. 1, 2021 | No Longer Used |
68001-0282-25 | 68001-0282 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 23, 2016 | Aug. 1, 2021 | No Longer Used |
68001-0282-26 | 68001-0282 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 23, 2016 | Aug. 1, 2021 | No Longer Used |
68001-0282-27 | 68001-0282 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 23, 2016 | Aug. 1, 2021 | No Longer Used |
68001-0284-25 | 68001-0284 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | May 31, 2016 | March 1, 2021 | In Use |
68001-0284-34 | 68001-0284 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | May 31, 2016 | March 1, 2021 | In Use |
68001-0425-35 | 68001-0425 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | July 7, 2020 | Aug. 11, 2021 | No Longer Used |
68001-0426-22 | 68001-0426 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | July 7, 2020 | Aug. 11, 2021 | No Longer Used |
Found 10,000 results in 6 milliseconds — Export these results